Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JPJuan‐juan PengNWNa WangJXJinghuan Xu

Discussion

Loading...

Member takes

Overview

Long-term follow-up shows improved progression-free survival in tp53-altered b-nhl with dual-target car t-cell therapy and stem cell transplant, suggesting an effective strategy for high-risk cases.

Key Points

  • This research examines the long-term effectiveness of dual-target CAR T-cell therapy in patients with TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma.
  • Conducted a long-term follow-up study with 122 patients
  • Patients received dual-target CAR T-cell therapy with or without autologous stem cell transplantation
  • TP53 mutation status evaluated via genomic analysis
  • TP53 alterations found in 48.4% of patients
  • Sequential ASCT-CAR-T approach significantly improved 5-year overall survival (70.2% vs. 40.0%)
  • Multivariate analysis identified not reaching remission at 3 months as a strong predictor for outcomes

Cite This Study

Peng et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df33https://doi.org/10.1182/blood-2025-3712
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term follow-up demonstrates the curative potential of dual CD19/CD22 CAR-T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma2026 · 3 citations
  2. 2Comparative efficacy and long-term survival of CD19/22 versus CD19 CAR-T immunotherapy in Relapsed/Refractory B-ALL with TP53 alterations2026 · 1 citations
  3. 3Impact of TP53 mutations on survival outcomes in the CAR-t era of large b-cell lymphoma2025 · 1 citations
  4. 4Impact of TP53 mutation on CD19-chimeric antigen receptor T-cell therapy in large B-cell lymphoma2025
  5. 5Long-term follow-up results of nonremission relapsed/refractory DLBCL with CAR T-cell cocktail therapy alone or in combination with ASCT2025